Poseida Therapeutics said that 21 of 23 patients (91%) responded to the allogeneic CAR-T therapy it’s developing with Roche ...

Kezar Life Sciences is suspending enrollment and dosing in a lupus trial after four patients died in the mid-stage study of ...

DCVC Bio confirmed it has put together a $400 million third fund, four years after raising $350 million in its sophomore ...

Prime Medicine announced Monday morning that it is cutting its pipeline, and it signed a T cell therapy partnership with ...

Roche is spending $850 million upfront to buy Regor Pharmaceuticals’ suite of next-generation CDK inhibitors as it doubles ...

As other young radiopharmaceutical companies get acquired by drugmakers, Boston-based Aktis Oncology wants to become one of ...